Indeed, blocking IL-1 signaling with monoclonal antibodies targeting the interleukin 1 receptor accessory protein (IL1RAP and IL1R3) has been shown to have an antileukemic effect on CML and AML cells in vivo [27,28]. The gene discussed is IL1RAP; the disease is acute myeloid leukemia.